• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 27, 2018

View Archived Issues

Bad actor in UC: Phase IIb futile for Protagonist, but understudy may perform

The surprise blowup of Protagonist Therapeutics Inc.'s PTG-100 for ulcerative colitis (UC) raised questions not only about the drug but also about the platform from which it emerged, with Stifel analyst Adam Walsh most pointedly interrogating company officials during a conference call to discuss the data. Read More

Clinical data and regulatory actions for March 26, 2018

Read More

Biohaven investors greet pivotal migraine studies with rough reception

Despite positive new pivotal data supporting its migraine treatment candidate, rimegepant, Biohaven Pharmaceutical Holding Co. Ltd. saw its shares (NYSE:BHVN) touch an all-time low Monday as investors fretted over the program's competitive stance in the crowded class of calcitonin gene-related peptide (CGRP) receptor antagonism. By day's end, the candidate's success in meeting the trials' co-primary endpoints appeared to soften the blow, leaving shares just 7.3 percent lower at $22.96. Read More

Verona shares go vroom-vroom on RPL-554 hit in maintenance COPD study

Shares of Verona Pharma plc closed up 31.7 percent on London's AIM (LSE:VRP) and spiked on Nasdaq (NASDAQ:VRNA) after top-line data showed that RPL-554 met its primary endpoint, producing clinically and statistically significant improvement in peak forced expiratory volume in one second (FEV1) at four weeks, compared to placebo, as a maintenance therapy in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Peak FEV1 was improved at all time points over the four weeks of dosing, confirming the therapy's bronchodilator effect, according to Verona officials. Read More

New approaches could broaden antibiotic space

Physiologically, antibodies are one of the major weapons the body deploys against infection. And the very first Nobel Prize in Physiology or Medicine, in 1901, was awarded to Emil Adolf von Behring for antibodies (in the form of serum therapy) against the diphtheria-causing Corynebacterium diphtheriae. So it is perhaps surprising that in the 117 years since, as far as antibiotic therapeutics go, small molecules have largely been the name of the game. Read More

Wyss Institute offers case study on how to bring engineering to biology to improve medicine

Reaching across disciplinary and institutional boundaries isn't necessarily a strength of academics at elite institutions such as Harvard University. Concern about precisely that issue nearly undid the founding of the Wyss Institute for Biologically Inspired Engineering before it was even launched at Harvard in the beginning of 2009. Read More

Beyondspring setting sights on China, U.S. filings as plinabulin advances into phase III CIN trials

HONG KONG – After a successful phase II study, Beyondspring Inc.'s plinabulin is set to enter the phase III global trial known as Study 105 to test the drug's efficacy in preventing chemotherapy-induced neutropenia (CIN) associated with docetaxel. Read More

Financings

Cohbar Inc., of Menlo Park, Calif., proposed a private placement of up to $55 million in nonconvertible unsecured promissory notes to certain arm's-length and non-arm's-length lenders.  Read More

Other news to note

Forma Therapeutics Inc., of Watertown, Mass., said it is collaborating with Boulder, Colo.-based Arpeggio Biosciences Inc. to utilize its technology to supplement the company's analysis of the biological effects of its potential drug candidates.  Read More

Regulatory front

The U.S. Trade Representative (USTR) filed a request for consultations with China at the World Trade Organization (WTO) to address China's technology practices that the U.S. claims run counter to WTO rules and result in unfair treatment for U.S. companies and innovators trying to do business in China.  Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe